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INTRODUCTION 
 C-type natriuretic peptide (CNP) plays a key role in regulating vascular homeostasis; 
the peptide controls local blood flow and systemic blood pressure, reduces the reactivity of 
leukocytes and platelets, and prevents the development of atherogenesis and aneurysm1-3. 
The expression of CNP in endothelial cells accounts for its predominant localization in 
mammals (in addition to the CNS), but CNP is also found in cardiomyocytes4, 5 and levels are 
upregulated in failing hearts6, 7. In accord with this additional cardiac localization, CNP has 
an established pharmacodynamic profile in modulating heart structure and function. For 
example, acutely CNP primarily exerts a negative inotropic and chronotropic action, partly via 
inhibition of L-type calcium currents8, 9. In the longer term, over-expression of a dominant 
negative form of natriuretic peptide receptor (NPR)-B (a guanylyl cyclase-coupled cognate 
receptor for CNP10-12) in cardiomyocytes results in accelerated development of cardiac 
hypertrophy, fibrosis and contractile dysfunction13. Indeed, there appears to be greater 
expression of NPR-B versus NPR-A (the cognate receptor for atrial and brain natriuretic 
peptides, ANP and BNP) during the development of cardiac hypertrophy, raising the 
possibility that CNP takes on the mantle of natriuretic peptide guardian of cardiac integrity14. 
This concept is reinforced by the observations that CNP protects against myocardial 
infarction (MI)-induced hypertrophy15, 16, that cardiac production of CNP increases 
substantially and correlates with severity in patients with heart failure (HF)17-19, and that the 
chimeric CD-NP exerts a potent beneficial effect in pre-clinical models of cardiac fibrosis20. 
Our own work has shown that administration of synthetic CNP protects against MI via 
activation of NPR-C (i.e. a cGMP-independent action)21. Evidence also supports a role for 
CNP in the right ventricle (RV) and in the pulmonary circulation22-24. Thus, there is strong 
evidence supporting a role for CNP in both right- and left- heart morphology & contractility. 
Consequently, the peptide has been tentatively termed a ‘cardiac natriuretic peptide25; yet, a 
(patho)physiological function in this context has not been established. 
Herein, we employed in vitro and in vivo models and unique transgenic strains with 
cardiomyocyte (cmCNP-/-), endothelial (ecCNP-/-) and fibroblast (fbCNP-/-) -specific CNP 
deletion, to define the peptide as a critical player in cardiac structure, ventricular contractility, 
and coronary reactivity; additionally, proof-of-concept is demonstrated for pharmacological 
targeting of this novel pathway in HF and ischaemia cardiovascular disorders. 
 
 
METHODS 
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Experimental HF models 
 Pressure-overload (abdominal aortic constriction; AAC) and sympathetic 
hyperactivation (isoprenaline; ISO) models of LVH and cardiac dysfunction were employed 
as previously described26 (see Supplemental Data for further information). 
 
Primary cardiomyocyte & cardiac fibroblast isolation and culturing 
 The Pierce primary cardiomyocyte isolation kit (Thermo Scientific, Loughborough, UK) 
was used to isolate neonatal cardiomyocytes from WT and cmCNP-/- mice. Cardiac 
fibroblasts from adult WT and fbCNP-/- animals were isolated by outgrowth from 1mm3 
sections of heart tissue. Further information is provided in Supplementary Data. 
 
Quantitative RT-PCR & immunoblotting 
 mRNA and protein expression were analysed using standard protocols (explicit 
information is provided in Supplementary Data). Specific primers for hypertrophic and fibrotic 
markers and housekeeping genes RLP-19 and β-actin are detailed in Supplementary Table 
1. 
 
Ex-vivo assessment of coronary vascular reactivity & I/R injury 
 Coronary reactivity and myocardial ischaemia/reperfusion (I/R) injury were evaluated 
in murine hearts set-up in Langendorff mode as we have described previously21, 26. More 
detailed protocols are provided in the Supplementary Data. 
 
Data analysis 
All data are reported as mean ± SD, where n is the number of mice used. Statistical 
analyses were conducted using GraphPad Prism (version 7; GraphPad software, California, 
USA). For comparison of two groups of data, a two-tailed, unpaired Student’s t-test was used. 
When comparing three or more groups of data one-way or two-way ANOVA followed by a 
Šídák multiple comparisons test was used with adjustment for multiplicity. P<0.05 was 
considered statistically significant and the P values presented in each Figure indicate all 
comparisons undertaken. 
 
 
RESULTS 
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Genetic deletion of CNP from cardiomyocytes has modest effects on basal cardiac 
function 
 Loss of cardiomyocyte CNP did not significantly alter any cardiac echocardiographic 
parameters with the exception of an increase in RR and QA interval, indicative of a basal 
decrease in heart rate (Figure 1 and Supplementary Table 2). This was substantiated by 
radiotelemetric analysis; cmCNP-/- mice maintained a normal circadian rhythm and exhibited 
no difference in blood pressure (Figure 1), but had a significantly lower heart rate (~20bpm) 
compared to WT littermates (Figure 1). 
 
Cardiomyocyte-specific deletion of CNP worsens phenotype following cardiac stress 
 A common detrimental phenotype manifested in cmCNP-/- mice in response to cardiac 
stress. Breeding females (heterozygous) animals exhibited a progressive deterioration in 
contractile function and LV dilatation with successive pregnancies, which resulted in 
significant mortality (Supplementary Figure 2). This deleterious response was mirrored in 
two independent pre-clinical models of HF; pressure overload and sympathetic 
hyperactivation. Cardiomyocyte-specific deletion of CNP resulted in a significantly greater 
reduction in ejection fraction, exacerbated LV dilatation, and more pronounced fibrosis (ie. 
collagen deposition) and cardiomyocyte enlargement compared to WT littermates (Figures 
2 & 3; with a trend towards greater LV weight). The adverse outcome in cmCNP-/- animals 
neither resulted from an indirect effect on blood pressure (pressure overload; Figure 2) nor 
changes in sympathetic responsiveness (i.e. HR; isoprenaline; Figure 3). 
 
NPR-C activation underpins the cardioprotective function of CNP 
 NPR-C-/- mice exhibited a significantly worse phenotype in all aspects of cardiac 
structure and function in response to pressure overload (Figure 4); indeed, this was arguably 
more severe than that apparent in cmCNP-/- animals (Figures 2 & 3). In sharp contrast, the 
phenotype of NPR-B-/- mice in response to sympathetic hyperactivation was mild or non-
existent (Supplementary Figure 3; the dwarfism and early death in NPR-B-/-11 severely limits 
study of cardiovascular biology but it was feasible to implant osmotic minipumps to deliver 
isoprenaline). Furthermore, therapeutic delivery of CNP (resulting in ~10-fold increase in 
circulating [CNP]; Supplementary Table 3) was able to substantially reverse the cardiac 
structural and functional deficits resulting from pressure overload in WT, but not NPR-C-/- 
mice (Figure 5), confirming that activation of this cognate receptor is responsible for 
conveying the cardioprotective effects of CNP. 
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 In human hearts the primary cellular localisation of NPR-C is the cardiomyocyte, with 
greater expression in failing versus healthy hearts (albeit reduced in murine models; 
Interestingly however, cardiac fibroblast co-localisation of NPR-C appears to be exclusive to 
disease (Figure 6). Indeed, CNP expression is reduced in failing hearts in both humans and 
mouse models, whereas NPR-B levels remain consistent across species and pathological 
status (Figure 6). Despite this profile, circulating CNP concentrations were unchanged in WT, 
cmCNP-/- or NPR-C-/- mice following AAC (Supplementary Figure 4). Moreover, plasma 
levels of ANP and BNP were consistent across genotypes following AAC, although there was 
some evidence of a subtle up-regulation of both peptides in response to loss of 
cardiomyocyte-derived CNP (Supplementary Figure 4). 
 
CNP prevents hypertrophy in isolated cardiomyocytes 
 Basal cardiomyocyte size was not different between WT and cmCNP-/-, but the in vitro 
hypertrophic response to Ang II was significantly greater in cmCNP-/- (Figure 5). Moreover, 
the hypertrophic response to Ang II in cmCNP-/- cells could be rescued to WT levels with the 
addition of exogenous CNP (Figure 5), confirming a key anti-hypertrophic activity of the 
peptide. 
 
The beneficial effects of cardiomyocyte-derived CNP are but not NO-dependent 
 Since Gi-coupled receptors (including NPR-C) have been shown to signal via eNOS 
phosphorylation the salutary effect of exogenous CNP in pressure overload-induced HF was 
examined in the presence of NOS inhibition. In this setting, the protective capacity of CNP 
was maintained (Supplementary Figure 5), intimating this beneficial pharmacodynamic 
action is not dependent on secondary generation of NO. 
 
The cardioprotective effects of CNP are linked to established hypertrophic and/or 
fibrotic pathways 
The favourable actions of CNP were confirmed at a more molecular level by comparing 
the expression of pro-hypertrophic and pro-fibrotic markers/drivers in cmCNP-/-, fbCNP-/- and 
NPR-C-/- animals. In all genotypes, ANP (↑), Col1α1 (↑), SERCA-2 (↓) and βMHC (↑) were 
altered in an analogous fashion; each of which is known to be modified in human HF and 
contribute to ventricular dysfunction (Supplementary Figure 6). Intriguingly, the effects on 
pro-fibrotic mediators were split; thus, fibronectin expression was increased in cmCNP-/- and 
NPR-C-/- mice whereas TGFβ was up-regulated in fbCNP-/- and NPR-C-/- animals. 
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A complementary role for fibroblast-derived CNP in heart failure 
 The accentuated severity in NPR-C-/- animals in the face of pressure overload (Figure 
5) intimated that CNP from a separate cellular source might play a functional role in triggering 
cardioprotective NPR-C. One possibility is that cardiac fibroblasts fulfil this capacity27. To 
explore this potential mechanism we generated a fibroblast-specific CNP knockout line 
(fbCNP-/-). Whilst there was no basal cardiac phenotype in these mice (Supplementary 
Figure 7) when exposed to pressure overload fbCNP-/- animals also exhibited an 
exacerbated phenotype compared to WT littermates (albeit more modest than that seen in 
cmCNP-/- or NPR-C-/- mice; Figure 7). However, identical studies conducted in ecCNP-/- 
animals suggest that endothelium-derived CNP plays little or no role in terms of 
cardioprotection during HF (Supplementary Figure 4). 
 
Endothelium-derived CNP regulates coronary reactivity via NPR-C 
 Bradykinin (BK), acetylcholine (ACh) and flow-mediated dilatation (i.e. acute increases 
in shear stress) elicited endothelium-dependent decreases in coronary perfusion pressure 
(CPP; ie. vasodilatation) in WT mice that were significantly impaired in ecCNP-/- animals 
(Figure 8). However, responses to exogenous CNP and the direct-acting vasodilator SNP 
were unchanged, indicating the deficit was of endothelial origin (Supplementary Figure 8). 
Vasodilator responses to BK, ACh and flow-mediated dilatation were correspondingly 
diminished in NPR-C-/- hearts (Figure 8), as was the vasodilator response to exogenous CNP 
(Supplementary Figure 8; although a residual drop in CPP persisted, likely due to activation 
of NPR-B2, 3). Finally, release of CNP into the coronary effluent was markedly reduced in 
hearts from ecCNP-/- mice in response to ACh (Supplementary Figure 8). 
 
Cardiomyocyte-derived CNP protects against ischemia-reperfusion injury 
Genetic ablation of cardiomyocyte-derived resulted in a significantly greater infarct 
area and prolonged impairment in LV function following I/R injury (Figure 8). In contrast, 
hearts from ecCNP-/- mice behaved in an ostensibly identical fashion to WT littermates 
(Supplementary Figure 8).The phenotype in NPR-C-/- animals recapitulated that observed 
in the cmCNP-/- mice (Figure 8). These data suggest that a NPR-C-triggered pathway 
underpins the cardioprotection proffered by cardiomyocyte-derived CNP following I/R injury.  
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DISCUSSION 
 The present study tenders definitive evidence for major physiological and pathological 
roles for CNP in the regulation of cardiac structure and function. Cardiomyocyte-derived CNP 
has a subtle effect on basal cardiac function with a modest fall in HR in cmCNP-/- mice (that 
is circadian rhythm and blood pressure –independent). Published evidence points to a dual 
role of CNP and/or NPR-C in sinoatrial node conduction28, heart rate (variability)29, and 
susceptibility to arrhythmia28, 29, perhaps via reductions in cardiac sympathetic 
transmission30. Such actions of CNP may represent an important protective mechanism and 
potential therapeutic target in HF patients as damping sympathetic activity improves 
survival31, 32. Preliminary evidence that cardiomyocyte-derived CNP might play a more 
substantive role in the response to cardiac stress was provided by a serendipitous 
observation of early mortality in breeding females in which LV hypertrophy during pregnancy 
accommodates the needs of the foetus. Accordingly, irrespective of the precipitating stimulus 
(i.e. pressure overload or sympathetic hyperactivation), cmCNP-/- mice fared worse with 
respect to several indices of cardiac structural and functional integrity in experimental HF; 
isolated cardiomyocytes from cmCNP-/- animals also exhibited an exaggerated hypertrophic 
response in vitro. These findings corroborate the concept of CNP as a ‘cardiac natriuretic 
peptide’25 and extends the cohort of natriuretic peptides key to heart health and disease 
above and beyond ANP and BNP. 
 Subsequent studies verified the NPR signalling mechanism responsible for the 
cardioprotective influence of CNP. The phenotype of NPR-C-/- mice following pressure 
overload mirrored that observed in cmCMP-/- animals; indeed, if anything the severity was 
greater. It is possible this aggravated cardiac dysfunction is due to lack of complete deletion 
of CNP from cardiomyocytes in cmCNP-/-. However, this dichotomy also raises the possibility 
that alternate cellular sources of CNP might contribute to cardioprotection. Endothelium-
restricted CNP deletion did not result in a worse phenotype in the face of pressure overload. 
However, an alternate hypothesis is that this supply might be from the cardiac fibroblast, 
since CNP is synthesized and secreted from these cells27. In order to provide proof-of-
concept to support this hypothesis, we developed a unique fibroblast-specific CNP null 
mutant and exposed these mice to pressure overload. Whereas basal cardiac functional 
parameters and MABP were not significantly disturbed, fbCNP-/- mouse did exhibit a modestly 
more severe phenotype following abdominal aortic constriction. This finding supports the 
thesis that cardiac fibroblasts synthesize and release CNP in response to cardiac stress that 
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complements the protective function of cardiomyocyte-derived CNP. This was corroborated 
by more molecular investigation in which ANP, βMHC and Col1α1 were up-regulated, and 
SERCA-2 down-regulated, in all gene knockout strains, exemplifying common mechanisms 
underpinning the beneficial effects of CNP/NPR-C signalling. These observations fit well with 
previous work verifying that CNP directly inhibits collagen synthesis in cardiac fibroblasts27. 
Finally, upregulation of critical pro-fibrotic mediators, TGFβ and fibronectin, was observed in 
fbCNP-/- and cmCNP-/- mice, respectively; changes in both were found in NPR-C-/- hearts. 
This finding suggests that to exert its maximal anti-fibrotic capacity, CNP release from both 
cardiomyocytes and cardiac fibroblasts is essential. However, the beneficial bioactivity of 
CNP in HF appears to be NOS independent. 
Intriguingly, the detrimental response to cardiac stress was not recapitulated in NPR-
B-/- mice. Such data support the conclusion that NPR-C, rather than NPR-B, is the principal 
mechanism via which CNP exerts its cardioprotective effect. This fits well with recent data in 
a cardiomyocyte-specific NPR-B-/- strain that exhibits a negligible intrinsic phenotype in 
response to pressure overload33, diminished ventricular expression of NPR-B in HF patients7, 
impaired sinoatrial conduction and aggravated atrial fibrosis in NPR-C-/- mice28, a human 
NPR-C genetic variant that precipitates LV dysfunction34, and corroborated herein by 
pharmacological delivery of CNP which completely reversed the structural and functional 
deficits associated with pressure overload in WT, but not NPR-C-/-, mice (although some 
recent reports have proposed a protective outcome following NPR-C deletion or antagonism 
in experimental HF35, 36). The fact that CNP was able to restore heart morphology and 
contractility in WT mice exposed to pressure overload suggests that even in the presence of 
endogenous CNP it is possible to boost NPR-C-dependent signalling for therapeutic gain. In 
fact, this study reveals that ventricular specimens from HF patients and healthy controls have 
a predominant cardiomyocyte expression of NPR-C whereas in failing hearts additional 
fibroblast localisation is observed; such findings support the concept that CNP-dependent 
NPR-C activation on both cardiomyocytes and fibroblasts drives the cardioprotective actions 
of the peptide. Additionally, it is demonstrated herein that ventricular CNP expression is 
diminished in murine pressure overload and human HF, whereas NPR-C levels are 
augmented (at least in human ventricular tissue); this hints that pharmacological 
administration of CNP or NPR-C agonists may be even more efficacious in HF patients. 
However, there is a disconnect between these observations and previous studies reporting 
increased myocardial CNP release and plasma CNP levels in patients with HF17-19. Whether 
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this results from the short-term nature of the experimental model utilised herein, and that 
more chronic release of CNP (as an intrinsic protective mechanism) is required to sustain 
elevated plasma concentrations, remains to be clarified. It might also be hypothesised that 
endothelial CNP release, rather than myocardial, contributes predominantly to the higher 
circulating levels of the peptide in HF patients. Nevertheless, there was a significant increase 
in plasma BNP (and a trend in ANP) in cmCNP-/- mice with HF, perhaps indicative of the 
exacerbated phenotype and/or an intrinsic mechanism compensating for loss of 
cardiomyocyte-derived CNP. Yet, an extensive literature supports the concept that both ANP 
and BNP exclusively exert their beneficial vascular (e.g. vasodilatation, diuretic) and cardiac 
(e.g. anti-hypertrophic) actions via activation of NPR-A since such responses are completely 
abrogated in NPR-A-/- mice, either following global or cell-specific deletion37-41. This suggests 
that NPR-C activation plays little or no role in any compensatory cardio- and/or vaso- 
protective roles of ANP and BNP, despite the fact that both peptides bind NPR-C12. Moreover, 
this study provides evidence that natriuretic peptide levels are not significantly altered in 
NPR-C-/- KO following pressure overload (mirroring measurements under physiological 
conditions42), ruling out an indirect effect (i.e. clearance) of NPR-C on the cardiac phenotype 
in these animals (albeit one would predict a better, not aggravated, outcome in mice lacking 
NPR-C). In contrast, augmentation of natriuretic peptide bioactivity is thought to underpin the 
efficacy of the dual neprilysin/angiotensin receptor blocker LCZ696 (Entresto) in HF43; 
indeed, since CNP is the most susceptible of the natriuretic peptides to neprilysin 
degradation44 it might be postulated that this member of the family would contribute the 
greatest cardioprotective influence. 
CNP also plays a fundamental role in the maintenance of myocardial perfusion. Mice 
with endothelial-restricted deletion of CNP exhibit a sharp reduction in the responsiveness to 
endothelium-dependent dilators and shear stress in the coronary circulation. Moreover, this 
deficiency in accompanied by a significant decrease in the release of CNP from the coronary 
vasculature, substantiating the link between endothelium-derived CNP and coronary 
homeostasis; such observations also dovetail well with shear stress as a key trigger for 
endothelial CNP release45. In conduit vessels CNP-induced relaxation is NPR-B-dependent10 
but in the resistance vasculature the importance of NPR-C in the vasoreactivity of CNP 
increases1. This is illustrated by the normotensive phenotype of NPR-B-/- mice1, 2, 11 versus 
the hypertension in ecCNP-/- animals1, 2. In the present study, coronary endothelium-
dependent vasoreactivity and responsiveness to exogenous CNP were markedly blunted in 
NPR-C-/- mice, implying that NPR-C activation primarily underpins the coronary actions of 
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CNP. This clear delineation of a CNP/NPR-C signal transduction system adds significantly to 
the understanding of mechanisms underpinning coronary vascular homeostasis, and is likely 
to have important implications for heart disease. For example, the ability of endothelium-
derived CNP to regulate coronary vascular reactivity, coupled to its pronounced effect on 
leukocyte flux, platelet function and atheroma1, suggests mimicking CNP bioactivity 
pharmacologically is likely to be an effective means by which to slow the progression of 
coronary artery disease. Moreover, coronary microvascular dysfunction is a hallmark of HF 
with preserved ejection fraction (HFpEF); promoting or recapitulating the bioactivity of 
endothelium-derived CNP might represent a new approach to reversing this issue as a 
disease-modifying therapy. 
 CNP/NPR-C signalling is also important in innate defence against I/R injury. However, 
in this context, it is cardiomyocyte, rather than endothelium, -derived CNP that appears key. 
This is perhaps surprising since the restoration of flow (i.e. reperfusion) should trigger the 
release of CNP from the coronary endothelium (as demonstrated above). Yet, genetic 
ablation of endothelium-derived CNP does not affect outcome. Mirroring observations in the 
coronary vasculature, genetic deletion of NPR-C recapitulates the unfavourable phenotype 
in hearts from cmCNP-/- following I/R. These data reveal a novel intrinsic capacity of the 
myocardium to protect itself against I/R injury via release of cardiomyocyte-derived CNP and 
autocrine activation of NPR-C (a role for NPR-B has also been previously reported13, 46). 
Indeed, the cardioprotective potential of CNP/NPR-C signalling is likely to be underestimated 
in the present study because they were conducted in the absence of blood perfusion; the 
well-established pathological roles of leukocytes and platelets in MI should also be dampened 
by NPR-C activation1, reducing further the extent of damage. Further investigation is 
warranted to define the underlying salutary pathways. It is well established that KATP channel 
opening is protective in IR injury and members of the KATP family are opened by the βγ-
subunits of Gi-coupled NPR-C21, 47, suggesting the beneficial effect of CNP against I/R injury 
might be mediated via such a mechanism, as we have described ex vivo21. In support of this 
concept, elevated Nppc and Npr3 mRNA expression is found in ischaemic hearts18. 
 In sum, herein we define CNP of cardiomyocyte, endothelium, and cardiac fibroblast 
origins as a key player in the physiological maintenance of coronary vascular homeostasis 
and host response to cardiac stress. These cardioprotective functions of CNP are mediated 
predominantly via activation of Gi-coupled NPR-C, identifying a new target in the fight against 
ischemic cardiovascular disorder and HF. 
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FIGURE LEGENDS 
 
Figure 1. Cardiomyocyte-specific ablation of CNP has modest effects on basal cardiac 
function. 24 hr and mean radiotelemetry evaluation of (A & B) MABP, (C & D) heart rate 
and (E & F) QA interval in WT and cmCNP-/- mice. (G) Echocardiographic analyses of left 
ventricular internal diameter at systole (LVIDs), left ventricular posterior wall diameter at 
systole (LVPWs), ejection fraction, left ventricle to body weight ratio (LV/BW), intraventricular 
septum diameter at systole (IVSs) and RR interval in WT and cmCNP-/- animals. Data are 
presented as mean ± SD and analysed using two-way ANOVA with Šídák post-hoc test (A, 
C & E) or Student’s t-test (B, D, F & G). Each statistical comparison undertaken has an 
assigned P value (adjusted for multiplicity). 
 
Figure 2. Cardiomyocyte-specific deletion of CNP worsens the cardiac response to 
pressure-overload. Ejection fraction (A), left ventricular internal diameter at systole (LVIDs; 
B), left ventricle to body weight ratio (LV/BW; C), mean arterial blood pressure (MABP; D), 
fibrotic burden (collagen fraction; E & G; scale bar = 50μm) and cardiomyocyte size (F & H) 
in WT and cmCNP-/- animals exposed to 6 weeks abdominal aortic constriction (AAC). Data 
are presented as mean ± SD and analysed using one-way ANOVA with Šídák post-hoc test. 
 
Figure 3. Cardiomyocyte-specific deletion of CNP worsens the cardiac response to 
sympathetic hyperactivation. Ejection fraction (A), left ventricular internal diameter at 
systole (LVIDs; B), left ventricle to body weight ratio (LV/BW; C), mean arterial blood pressure 
(MABP; D), fibrotic burden (collagen fraction; E & G; scale bar = 50μm) and cardiomyocyte 
size (F & H) in WT and cmCNP-/- animals exposed to 7 days isoprenaline (ISO; 20mg/kg/day). 
Data are presented as mean ± SD and analysed using one-way ANOVA with Šídák post-hoc 
test. 
 
Figure 4. Global deletion of NPR-C worsens the cardiac response to pressure-
overload. Ejection fraction (A), left ventricular internal diameter at systole (LVIDs; B), left 
ventricle to body weight ratio (LV/BW; C), mean arterial blood pressure (MABP; D), fibrotic 
burden (collagen fraction; E & G; scale bar = 50μm) and cardiomyocyte size (F & H) in WT 
and NPR-C-/- animals exposed to 6 weeks abdominal aortic constriction (AAC). Data are 
presented as mean ± SD and analysed using one-way ANOVA with Šídák post-hoc test. 
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Figure 5. Pharmacological administration of CNP rescues the detrimental cardiac 
phenotype in response to pressure-overload in cmCNP-/-, but not NPR-C-/-, mice. 
Ejection fraction (A), mean arterial blood pressure (MABP; B), and fibrotic burden (collagen 
fraction; C & D; scale bar = 50μm) in WT or NPR-C-/- animals exposed to 6 weeks abdominal 
aortic constriction (AAC) in the absence and present of CNP (0.2μg/kg/day; s.c. by osmotic 
minipump, initiated 3 weeks following AAC surgery and maintained throughout the study). 
Data are presented as mean ± SEM. *P<0.05, **P<0.01, ***P<0.001 vs. sham treatment of 
corresponding genotype. #P<0.05, ##P<0.01 vs. WT AAC. n=6-8. Intrinsic hypertrophic 
response and the effect of CNP (100nM) on cardiomyocytes isolated from WT and cmCNP-/- 
mice (E & F). Data are presented as mean ± SD and analysed using one-way ANOVA with 
Šídák post-hoc test. 
 
Figure 6. Expression and co-localisation of CNP and NPR-C are altered in human heart 
failure. CNP, NPR-B and NPR-C mRNA (and protein) expression in murine pressure 
overload–induced (6 weeks abdominal aortic constriction, AAC) heart failure (A) and in 
human non-failing (NF) and failing (HF) hearts (B). NPR-C is highly expressed on 
cardiomyocytes in both non-failing and failing hearts but co-localizes with cardiac fibroblasts 
in heart failure patients (C; cardiomyocyte marker troponin T; fibroblast marker vimentin; 
scale bars, 50x magnification; white triangles highlight NPR-C co-localization in fibroblasts in 
HF). Data are presented as mean ± SD and analysed using Student’s t-test. 
 
Figure 7. Fibroblast-specific deletion of CNP worsens the cardiac response to 
pressure-overload. Ejection fraction (A), left ventricular internal diameter at systole (LVIDs; 
B), left ventricle to body weight ratio (LV/BW; C), mean arterial blood pressure (MABP; D), 
fibrotic burden (collagen fraction; E & G; scale bar = 50μm) and cardiomyocyte size (F & H) 
in WT and fbCNP-/- animals exposed to 6 weeks abdominal aortic constriction (AAC). Data 
are presented as mean ± SD and analysed using one-way ANOVA with Šídák post-hoc test. 
 
Figure 8. Endothelial CNP regulates coronary vascular reactivity and 
ischaemia/reperfusion injury via NPR-C. (A & B) Bradykinin (10 nmol), (C & D) 
acetylcholine (0.1-1 nmol), and (E & F) flow-mediated dilatation (zero flow for 20-80 s followed 
by reperfusion at 2 ml/min) –dependent decreases in coronary perfusion pressure (CPP) in 
isolated Langendorff hearts from WT, ecCNP-/- and NPR-C-/- mice. (G & H) Infarct size and 
(I & J) left ventricular developed pressure (LVDP) in isolated Langendorff hearts from WT, 
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cmCNP-/- and NPR-C-/- mice subjected to 25 mins global ischaemia (zero flow) followed by 
90 mins reperfusion (2 ml/min constant flow). Data are presented as mean ± SD and analysed 
using two-way ANOVA with Šídák post-hoc test (C, D, E, F, I & J) or Student’s t-test (A, B, 
G & H).  
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